Tryptophan research in panic disorder

International Journal of Tryptophan Research

Volumn 1, Issue 1, 2008, Pages 3-10

  Maron, Eduard ^a,b   Shlik, Jakov ^c   Nutt, David J ^d  

^a North Estonian Regional Hospital   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Anxiety; Challenge; Gene; Panic disorder; Tryptophan

Indexed keywords

EID: 84859075727     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/ijtr.s929     Document Type: Review

References (77)

1. Argyropoulos, S.V., Hood, S.D., Adrover, M., Bell, C.J., Rich, A.S., Nash, J.R., Rich, N.C., Witchel, H.J. and Nutt, D.J. 2004. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol. Psychiatry, 56:503-9.
2. Barr, L.C., Goodman, W.K., McDougle, C.J., Delgado, P.L., Heninger, G.R., Charney, D.S. and Price, L.H. 1994. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch. Gen. Psychiatry, 51:309-17.
3. Bell, C., Forshall, S., Adrover, M., Nash, J., Hood, S., Argyropoulos, S., Rich, A. and Nutt, D.J. 2002. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J. Psychopharmacol., 16:5-14.
4. Bell, C.J., Hood, S.D. and Nutt, D.J. 2005. Acute tryptophan depletion. Part II: clinical effects and implications. Aust N Z J. Psychiatry, 39:565-74.
5. Berney, A., Nishikawa, M., Benkelfat, C., Debonnel, G., Gobbi, G. and Diksic, M. 2008. An index of 5-HT synthesis changes during early antidepressant treatment: alpha-[11C]methyl-L-tryptophan PET study. Neurochem. Int., 52:701-8.
6. Berney, A., Sookman, D., Leyton, M., Young, S.N. and Benkelfat, C. 2006. Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol. Psychiatry, 59:853-7.
7. Birdsall, T. 1998. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern. Med. Rev., 3:271-80.
8. Breidenthal, S.E., White, D.J. and Glatt, C.E. 2004. Identification of genetic variants in the neuronal form of tryptophan hydroxylase (TPH2). Psychiatr. Genet., 14:69-72.
9. Charig, E.M., Anderson, I.M., Robinson, J.M., Nutt, D.J. and Cowen, P.J. 1986. L-typtophan and prolactin release: evidence for interaction between 5HT1 and 5HT2 receptors. Hum. Psychopharmacol., 1:93-97.
10. Charney, D. and Heninger, G. 1986. Serotonin function in panic disorders. The effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment. Arch. Gen. Psychiatry, 43:1059-65.
11. Charney, D.S., Heninger, G.R., Reinhard, JF Jr, Sternberg, D.E. and Hafstead, K.M. 1982. The effect of IV L-tryptophan on prolactin, growth hormone, and mood in healthy subjects. Psychopharmacology, 78(1):38-43.
12. Coon, H., Dunn, D., Lainhart, J., Miller, J., Hamil, C., Battaglia, A., Tancredi, R., Leppert, M.F., Weiss, R. and McMahon, W. 2005. Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2). Am. J. Med. Genet. B. Neuropsychiatr. Genet., 135:42-6.
13. Davies, S.J., Hood, S.D., Argyropoulos, S.V., Morris, K., Bell, C., Witchel, H.J., Jackson, P.R., Nutt, D.J. and Potokar, J.P. 2006. Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. J. Clin. Psychopharmacol., 26(4):414-8.
14. Deakin, JFW. 1996. 5-HT, antidepressant drugs and the psychosocial origins of depression. J. Psychopharmacol., 10:31-8.
15. Deakin, JFW. and Graeff, F. 1991. 5-HT and mechanisms of defence. J. Psychopharmacol., 5:305-15.
16. De Luca, V., Mueller, D.J., Tharmalingam, S., King, N. and Kennedy, J.L. 2004. Analysis of the novel TPH2 gene in bipolar disorder and suicidality. Mol. Psychiatry, 9:896-7.
17. De Luca, V., Voineskos, D., Wong, G.W., Shinkai, T., Rothe, C., Strauss, J. and Kennedy, J.L. 2005. Promoter polymorphism of second tryptophan hydroxylase isoform (TPH2) in schizophrenia and suicidality. Psychiatry Res., 134:195-8.
18. den Boer, J.A. and Westenberg, H.G. 1990. Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res., 31:267-78.
19. Dreshfield-Ahmad, L., Thompson, D., Schaus, J. and Wong, D. 2000. Enhancement in extracellular serotonin levels by 5-hydroxytryptophan loading after administration of WAY. 100635 and fluoxetine. Life Sci., 66:2035-41.
20. Eaton, W.W., Kessler, R.C., Wittchen, H.U. and Magee, W.J. 1994. Panic and panic disorder in the United States. Am. J. Psychiatry, 151:413-20.
21. Fehr, C., Schleicher, A., Szegedi, A., Anghelescu, I., Klawe, C., Hiemke, C. and Dahmen, N. 2001. Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 25:965-82.
22. Fickbohm, D.J. and Katz, P.S. 2000. Paradoxical actions of the serotonin precursor 5-hydroxytryptophan on the activity of identified serotonergic neurons in a simple motor circuit. J. Neurosci., 20:1622-34.
23. Garriock, H.A., Allen, J.J., Delgado, P., Nahaz, Z., Kling, M.A., Carpenter, L., Burke, M., Burke, W., Schwartz, T., Marangell, L.B., Husain, M., Erickson, R.P. and Moreno, F.A. 2005. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol. Psychiatry, 10:976-7.
24. Goddard, A.W., Charney, D.S., Germine, M., Woods, S.W., Heninger, G.R., Krystal, J.H., Goodman, W.K. and Price, L.H. 1995. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biol. Psychiatry, 38:74-85.
25. Goddard, A.W., Sholomskas, D.E., Walton, K.E., Augeri, F.M., Charney, D.S., Heninger, G.R., Goodman, W.K. and Price, L.H. 1994. Effects of tryptophan depletion in panic disorder. Biol. Psychiatry, 36:775-7.
26. Han, L., Nielsen, D.A., Rosenthal, N.E., Jefferson, K., Kaye, W., Murphy, D., Altemus, M., Humphries, J., Cassano, G., Rotondo, A., Virkkunen, M., Linnoila, M. and Goldman, D. 1999. No coding variant of the tryptophan hydroxylase gene detected in seasonal affective disorder, obsessive-compulsive disorder, anorexia nervosa, and alcoholism. Biol. Psychiatry, 45:615-9.
27. Harmer, C.J., Rogers, R.D., Tunbridge, E., Cowen, P.J. and Goodwin, G.M. 2003. Tryptophan depletion decreases the recognition of fear in female volunteers. Psychopharmacology, 167:411-7.
28. Harvey, M., Shink, E., Tremblay, M., Gagne, B., Raymond, C., Labbe, M., Walther, D.J., Bader, M. and Barden, N. 2004. Support for the involvement of TPH2 gene in affective disorders. Mol. Psychiatry, 9:980-1.
29. Hood, S.D., Bell, C.J. and Nutt, D.J. 2005. Acute tryptophan depletion. Part I: rationale and methodology. Aust. N Z J. Psychiatry, 39:558-64.
30. Hood, S.D., Hince, D.A., Robinson, H., Cirillo, M., Christmas, D. and Kaye, J.M. 2006. Serotonin regulation of the human stress response. Psychoneuroendocrinology, 31:1087-97.
31. Huwig-Poppe, C., Voderholzer, U., Backhaus, J., Riemann, D., König, A. and Hohagen, F. 1999. The tryptophan depletion test. Impact on sleep in healthy subjects and patients with obsessive-compulsive disorder. Adv. Exp. Med. Biol., 467:35-42.
32. Kahn, R. and Westenberg, H. 1985. L-5-hydroxytryptophan in the treatment of anxiety disorders. J. Affect Disord., 8:197-200.
33. Kahn, R., Westenberg, H., Verhoeven, W., Gispen-de Wied, C. and Kamerbeek, W. 1987. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int. Clin. Psychopharmacol., 2:33-45.
34. Kent, J., Coplan, J., Martinez, J., Karmally, W., Papp, L. and Gorman, J. 1996. Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report. Psychiatry Res., 64:83-90.
35. Klaassen, T., Klumperbeek, J., Deutz, N., van Praag, H. and Griez, E. 1998. Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge. Psychiatry Res., 77:167-74.
36. Koszycki, D., Zacharko, R., Le Melledo, J., Young, S. and Bradwejn, J. 1996. Effect of Acute Tryptophan Depletion on Behavioral, Cardiovascular, and Hormonal Sensitivity to Cholecystokinin-Tetrapeptide Challenge in Healthy Volunteers. Biol. Psychiatry, 40:648-55.
37. Külz, A.K., Meinzer, S., Kopasz, M. and Voderholzer, U. 2007. Effects of tryptophan depletion on cognitive functioning, obsessivecompulsive symptoms and mood in obsessive-compulsive disorder: preliminary results. Neuropsychobiology, 56:127-31.
38. Maron, E., Kuikka, J.T., Shlik, J., Vasar, V., Vanninen, E. and Tiihonen, J. 2004a. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res., 132:173-81.
39. Maron, E., Lang, A., Tasa, G., Liivlaid, L., Tõru, I., Must, A., Vasar, V. and Shlik, J. 2005a. Associations between serotonin-related gene polymorphisms and panic disorder. Int. J. Neuropsychopharmacol., 8:261-6.
40. Maron, E., Nikopensius, T., Kõks, S., Altmäe, S., Heinaste, E., Vabrit, K., Tammekivi, V., Hallast, P., Koido, K., Kurg, A., Metspalu, A., Vasar, E., Vasar, V. and Shlik, J. 2005b. Association study of 90 candidate genetic polymorphisms in panic disorder. Psychiatr. Genet., 15:17-24.
41. Maron, E. and Shlik, J. 2006. Serotonin function in panic disorder: important. but why? Neuropsychopharmacology, 1:1-11.
42. Maron, E., Tõru, I., Vasar, V. and Shlik, J. 2004b. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J. Psychopharmacol., 18:194-9.
43. Maron, E., Tõru, I., Must, A., Tasa, G., Toover, E., Vasar, V., Lang, A. and Shlik, J. 2007. Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. Neurosci. Lett, 411:180-4.
44. Meltzer, M., Bastani, M., Jayathilake, M. and Maes, M. 1997. Fluoxetine, but not Tricyclic Antidepressants, Potentiates the 5-Hydroxytryptophan-Mediated Increase in Plasma Cortisol and Prolactin Secretion in Subjects with Major Depression or with Obsessive Compulsive Disorder. Neuropsychopharmacology, 17:1-11.
45. Meltzer, H. and Maes, M. 1994. Effect of pindolol on the L-5-HTPinduced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacologia, 114:635-43.
46. Miller, H.E., Deakin, J.F. and Anderson, I.M. 2000. Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. Br. J. Psychiatry, 176:182-8.
47. Mössner, R., Freitag, C.M., Gutknecht, L., Reif, A., Tauber, R., Franke, P., Fritze, J., Wagner, G., Peikert, G., Wenda, B., Sand, P., Rietschel, M., Garritsen, H., Jacob, C., Lesch, K.P. and Deckert, J. 2006a. The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder. J. Psychopharmacol., 20:547-52.
48. Mössner, R., Walitza, S., Geller, F., Scherag, A., Gutknecht, L., Jacob, C., Bogusch, L., Remschmidt, H., Simons, M., Herpertz-Dahlmann, B., Fleischhaker, C., Schulz, E., Warnke, A., Hinney, A., Wewetzer, C. and Lesch, K.P. 2006b. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int. J. Neuropsychopharmacol, 9:437-42.
49. Nash, J.R., Sargent, P.A., Rabiner, E.A., Hood, S.D., Argyropoulos, S.V., Potokar, J.P., Grasby, P.M., Nutt, D.J. and (in press). A positron emission tomography study of serotonin 5-HT1A receptor availability in untreated and SSRI-recovered patients with panic disorder. B. J. Psych.
50. Neumeister, A., Bain, E., Nugent, A., Carson, R.E., Bonne, O., Luckenbaugh, D., Eckelman, W., Herscovitch, P., Charney, D. and Drevets, W. 2004. Reduced serotonin type 1A receptor binding in panic disorder. J. Neurosci., 24:589-91.
51. Nishizawa, S., Benkelfat, C., Young, S., Leyton, M., Mzengeza, S., de Montigny, C., Blier, P. and Diksic, M. 1997. Differences between males and females in rates of serotonin synthesis in human brain. Proc. Natl. Acad. Sci. U. S. A., 94:5308-13.
52. Nutt, D.J. 1998. Antidepressants in panic disorder: clinical and preclinical mechanisms. J. Clin. Psychiatry., 59:24-8.
53. Nutt, D.J., Forshall, S., Bell, C., Rich, A., Sandford, J., Nash, J. and Argyropoulos, S. 1999. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur. Neuropsychopharmacol, 9:81-6.
54. Pecknold, J.C., McClure, D.J., Appeltauer, L., Allan, T. and Wrzesinski, L. 1982. Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobic patients? Br. J. Psychiatry, 140:484-90.
55. Peters, E.J., Slager, S.L., McGrath, P.J., Knowles, J.A. and Hamilton, S.P. 2004. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry, 9:879-89.
56. Rosa-Neto, P., Diksic, M., Okazawa, H., Leyton, M., Ghadirian, N., Mzengeza, S., Nakai, A., Debonnel, G., Blier, P. and Benkelfat, C. 2004. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch. Gen. Psychiatry, 61:556-63.
57. Ruddick, J.P., Evans, A.K., Nutt, D.J., Lightman, S.L., Rook, G.A. and Lowry, C.A. 2006. Tryptophan metabolism in the central nervous system: medical implications. Expert. Rev. Mol. Med., 8:1-27.
58. Sakai, Y., Nishikawa, M., Leyton, M., Benkelfat, C., Young, S.N. and Diksic, M. 2006. Cortical trapping of alpha-[(11)C]methyll-tryptophan, an index of serotonin synthesis, is lower in females than males. Neuroimage., 33:815-24.
59. Schaechter, J.D. and Wurtman, R.J. 1990. Serotonin release varies with brain tryptophan levels. Brain Res., 532:203-10.
60. Schruers, K., Klaassen, T., Pols, H., Overbeek, T., Deutz, N. and Griez, E. 2000. Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. Psychiatry Res., 93:179-87.
61. Schruers, K., van Diest, R., Nicolson, N. and Griez, E. 2002a. L-5-hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology, 161:365-9.
62. Schruers, K., van Diest, R., Overbeek, T. and Griez, E. 2002b. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res., 113:237-43.
63. Sheehan, K., Lowe, N., Kirley, A., Mullins, C., Fitzgerald, M., Gill, M. and Hawi, Z. 2005. Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol. Psychiatry, 10:944-9.
64. Smeraldi, E., Diaferia, G., Erzegovesi, S., Lucca, A., Bellodi, L. and Moja, E.A. 1996. Tryptophan depletion in obsessive-compulsive patients. Biol. Psychiatry, 40:398-402.
65. Stoltenberg, S.F., Glass, J.M., Chermack, S.T., Flynn, H.A., Li, S., Weston, M.E. and Burmeister, M. 2006. Possible association between response inhibition and a variant in the brain-expressed tryptophan hydroxylase-2 gene. Psychiatr. Genet., 16:35-8.
66. Tõru, I., Shlik, J., Maron, E., Vasar, V. and Nutt, D.J. 2006. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacology, 186:107-12.
67. van Vliet, I.M., Slaap, B.R., Westenberg, H.G. and Den Boer, J.A. 1996. Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder. Eur. Neuropsychopharmacol., 6:103-10.
68. Walitza, S., Renner, T.J., Dempfle, A., Konrad, K., Wewetzer, Ch., Halbach, A., Herpertz-Dahlmann, B., Remschmidt, H., Smidt, J., Linder, M., Flierl, L., Knolker, U., Friedel, S., Schafer, H., Gross, C., Hebebrand, J., Warnke, A. and Lesch, K.P. 2005. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attentiondeficit/hyperactivity disorder. Mol. Psychiatry, 10:1126-32.
69. Walther, D.J., Peter, J.U., Bashammakh, S., Hortnagl, H., Voits, M., Fink, H. and Bader, M. 2003. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science, 299:76.
70. Young, S.N., Smith, S.E., Pihl, R.O. and Ervin, F.R. 1985. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology, 87:173-7.
71. Zill, P., Baghai, T.C., Zwanzger, P., Schule, C., Eser, D., Rupprecht, R., Möller, H.J., Bondy, B. and Ackenheil, M. 2004a. SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol. Psychiatry, 9:1030-6.
72. Zill, P., Buttner, A., Eisenmenger, W., Bondy, B. and Ackenheil, M. 2004b. Regional mRNA expression of a second tryptophan hydroxylase isoform in postmortem tissue samples of two human brains. Eur. Neuropsychopharmacol., 14:282-4.
73. Zill, P., Buttner, A., Eisenmenger, W., Möller, H.J., Bondy, B. and Ackenheil, M. 2004c. Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol. Psychiatry, 56:581-6.
74. Zhang, X., Beaulieu, J.M., Gainetdinov, R.R. and Caron, M.G. 2006. Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. Cell Mol. Life Sci., 63:6-11.
75. Zhang, X., Beaulieu, J.M., Sotnikova, T.D., Gainetdinov, R.R. and Caron, M.G. 2004. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science, 305:217.
76. Zhang, X., Gainetdinov, R.R., Beaulieu, J.M., Sotnikova, T.D., Burch, L.H., Williams, R.B., Schwartz, D.A., Krishnan, K.R. and Caron, M.G. 2005. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron, 45:11-16.
77. Zhou, Z., Roy, A., Lipsky, R., Kuchipudi, K., Zhu, G., Taubman, J., Enoch, M.A., Virkkunen, M. and Goldman, D. 2005. Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Arch. Gen. Psychiatry, 62:1109-18.